1. Home
  2. MREO vs BMRC Comparison

MREO vs BMRC Comparison

Compare MREO & BMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • BMRC
  • Stock Information
  • Founded
  • MREO 2015
  • BMRC 1989
  • Country
  • MREO United Kingdom
  • BMRC United States
  • Employees
  • MREO N/A
  • BMRC N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • BMRC Major Banks
  • Sector
  • MREO Health Care
  • BMRC Finance
  • Exchange
  • MREO Nasdaq
  • BMRC Nasdaq
  • Market Cap
  • MREO 438.8M
  • BMRC 416.8M
  • IPO Year
  • MREO N/A
  • BMRC N/A
  • Fundamental
  • Price
  • MREO $1.76
  • BMRC $23.78
  • Analyst Decision
  • MREO Strong Buy
  • BMRC Buy
  • Analyst Count
  • MREO 5
  • BMRC 4
  • Target Price
  • MREO $7.20
  • BMRC $25.50
  • AVG Volume (30 Days)
  • MREO 4.4M
  • BMRC 121.1K
  • Earning Date
  • MREO 08-12-2025
  • BMRC 07-28-2025
  • Dividend Yield
  • MREO N/A
  • BMRC 4.21%
  • EPS Growth
  • MREO N/A
  • BMRC N/A
  • EPS
  • MREO N/A
  • BMRC N/A
  • Revenue
  • MREO N/A
  • BMRC $70,630,000.00
  • Revenue This Year
  • MREO N/A
  • BMRC $60.39
  • Revenue Next Year
  • MREO $51.92
  • BMRC $10.56
  • P/E Ratio
  • MREO N/A
  • BMRC N/A
  • Revenue Growth
  • MREO N/A
  • BMRC N/A
  • 52 Week Low
  • MREO $1.57
  • BMRC $16.97
  • 52 Week High
  • MREO $5.02
  • BMRC $27.11
  • Technical
  • Relative Strength Index (RSI)
  • MREO 35.35
  • BMRC 45.68
  • Support Level
  • MREO $1.65
  • BMRC $24.57
  • Resistance Level
  • MREO $1.89
  • BMRC $25.40
  • Average True Range (ATR)
  • MREO 0.15
  • BMRC 0.62
  • MACD
  • MREO -0.03
  • BMRC -0.28
  • Stochastic Oscillator
  • MREO 12.84
  • BMRC 12.15

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About BMRC Bank of Marin Bancorp

Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.

Share on Social Networks: